Peripheral Arterial Disease - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Peripheral Arterial Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Peripheral Arterial Disease: Overview
Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking. Possible symptoms include: Hair loss on the feet and legs, Numbness in the legs, A foot or the lower leg may feel cold, and leg weakness. Symptoms and medical history are being questioned by the doctor for the appropriate diagnossi of peripheral arterial disease. PAD is usually treated by aggressively managing the risk factors with lifestyle changes and medication. This includes quitting smoking, controlling blood pressure and cholesterol, controlling diabetes, and losing weight. Surgery, medications and angioplasty are some other treatment options for peripheral arterial disease.
'Peripheral Arterial Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Peripheral Arterial Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peripheral Arterial Disease Emerging Drugs
Further product details are provided in the report
Peripheral Arterial Disease: Therapeutic Assessment
This segment of the report provides insights about the different Peripheral Arterial Disease drugs segregated based on following parameters that define the scope of the report, such as:
Peripheral Arterial Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease drugs.
Peripheral Arterial Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Peripheral Arterial Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Peripheral Arterial Disease: Overview
Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking. Possible symptoms include: Hair loss on the feet and legs, Numbness in the legs, A foot or the lower leg may feel cold, and leg weakness. Symptoms and medical history are being questioned by the doctor for the appropriate diagnossi of peripheral arterial disease. PAD is usually treated by aggressively managing the risk factors with lifestyle changes and medication. This includes quitting smoking, controlling blood pressure and cholesterol, controlling diabetes, and losing weight. Surgery, medications and angioplasty are some other treatment options for peripheral arterial disease.
'Peripheral Arterial Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease.
This segment of the Peripheral Arterial Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peripheral Arterial Disease Emerging Drugs
- Rivaroxaban: Janssen Pharmaceutical
- Semaglutide: Novo Nordisk
Further product details are provided in the report
Peripheral Arterial Disease: Therapeutic Assessment
This segment of the report provides insights about the different Peripheral Arterial Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Peripheral Arterial Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Peripheral Arterial Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease drugs.
Peripheral Arterial Disease Report Insights
- Peripheral Arterial Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peripheral Arterial Disease drugs?
- How many Peripheral Arterial Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peripheral Arterial Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Peripheral Arterial Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Peripheral Arterial Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Peripheral Arterial Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Peripheral Arterial Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Rivaroxaban: Janssen Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
JVS-100: Juventas Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
FGF-1:Venturis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Peripheral Arterial Disease Key Companies
Peripheral Arterial Disease Key Products
Peripheral Arterial Disease- Unmet Needs
Peripheral Arterial Disease- Market Drivers and Barriers
Peripheral Arterial Disease- Future Perspectives and Conclusion
Peripheral Arterial Disease Analyst Views
Peripheral Arterial Disease Key Companies
Appendix
Executive Summary
Peripheral Arterial Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Peripheral Arterial Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Peripheral Arterial Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Peripheral Arterial Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Rivaroxaban: Janssen Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
JVS-100: Juventas Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
FGF-1:Venturis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Peripheral Arterial Disease Key Companies
Peripheral Arterial Disease Key Products
Peripheral Arterial Disease- Unmet Needs
Peripheral Arterial Disease- Market Drivers and Barriers
Peripheral Arterial Disease- Future Perspectives and Conclusion
Peripheral Arterial Disease Analyst Views
Peripheral Arterial Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Peripheral Arterial Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Peripheral Arterial Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Peripheral Arterial Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Peripheral Arterial Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
